Beyond Air™ Scheduled to Announce Fiscal Year 2020 Financial Results on Monday, June 22nd
06/08/2020 - 05:29 PM
GARDEN CITY, N.Y., June 08, 2020 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and gaseous NO (gNO) for the treatment of solid tumors, today announced it will report financial results for its fiscal fourth quarter and year ended March 31, 2020 after the market closes on Monday, June 22, 2020. The Company’s management team is scheduled to host a conference call and webcast at 4:30 p.m. Eastern Time the same day.
100%; border-collapse:collapse !important;">Conference Call & Webcast Details: 12%; width:12% ; min-width:12% ;">Date and Time: 88%; width:88% ; min-width:88% ;">Monday, June 22nd @ 4:30 p.m. ET Domestic: 877-407-0784 International: 201-689-8560 Passcode: 13704923 Webcast: http://public.viavid.com/index.php?id=140183
About Beyond Air, Inc. www.beyondair.net
CONTACT Steven Lisi, Chief Executive Officer Slisi@beyondair.net
Corey Davis, Ph.D.cdavis@lifesciadvisors.com
XAIR Rankings
#5085 Ranked by Stock Gains
XAIR Stock Data
Industry
Other Industrial Machinery Manufacturing
Sector
Manufacturing
Tags
Technology Services, Packaged Software, Manufacturing, Other Industrial Machinery Manufacturing
Country
US
City
Garden City
About XAIR
Beyond Air, Inc. is a clinical-stage medical device and biopharmaceutical company developing a revolutionary NO Generator and Delivery System, LungFit™, that uses NO generated from ambient air to deliver precise amounts of NO to the lungs of ventilated and non-ventilated patients for the potential treatment of a variety of pulmonary diseases. LungFit™ can generate up to 400 ppm of NO for delivery either continuously or for a fixed amount of time, and has the ability to either titrate dose on demand or maintain a constant dose. The Company is currently applying its therapeutic expertise to develop treatments for pulmonary hypertension in various settings, in addition to treatments for respiratory tract infections that are not effectively addressed with current standards of care. Beyond Air is currently advancing its innovative LungFit™ in clinical trials for the treatment of severe lung infections such as SARS-CoV-2 and nontuberculous mycobacteria (NTM). Additionally, Beyond Air is performing preclinical testing of the use of ultra-high concentrations of NO with a proprietary delivery system, separate from LungFit™, to target certain solid tumors.
